Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316470 · ClinicalTrials.gov registry record · Phase 2
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
A Phase 2 study of Clostridium Difficile, sponsored by Valneva Austria.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 10
- Study locations
NCT02316470 is a Phase 2 study of Clostridium Difficile that has completed, run by Valneva Austria. The registered enrollment target is 500 participants, above the 378-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (32% higher). The trial reports 10 study locations across 6 states.
The verdict
NCT02316470, a Phase 2 study of Clostridium Difficile, has completed, sponsored by Valneva Austria.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4 parallel study groups. 500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a (3:3:3:1) ratio to receive either VLA84 75 µg w/o (without) Alum, VLA84 200 µg w/o Alum, VLA84 200 µg w/ (with) Alum (150 subjects each), or placebo (50 subjects), as i.m. (intramuscular) vaccinations into alternating arms, on Days 0, 7 and 28
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA84
Study Locations (10)
California
- eStudy Site, Chula Vista - Chula Vista
- eStudy Site, La Mesa - La Mesa
- eStudy Site, Oceanside - Oceanside
Other
- Berliner Zentrum für Reise- und Tropenmedizin - Berlin
- KFGN Klinische Forschung Hannover- Mitte GmbH - Hanover
- Klinik und Poliklinik für Innere Medizin der Universität Rostock - Rostock
Alabama
- Optimal Research LLC - Huntsville
Florida
- Optimal Research LLC - Melbourne
Illinois
- Optimal Research LLC - Peoria
Indiana
- Optimal Research LLC - Mishawaka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316470
The ClinicalTrials.gov registry entry for NCT02316470 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 378-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (32% higher). The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02316470 reports 10 study locations spanning 6 distinct geographic areas - top geographies include California, Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT02316470 about?
NCT02316470 is a clinical study titled "Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study". Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4 parallel study groups. 500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a (3:3:3:1) ratio to receive either VLA84 75 µg w/o (without) Alum, VLA84 200 µg w/o A...
What is the current status of trial NCT02316470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2014-12. Estimated completion is 2015-10.
What conditions does trial NCT02316470 study?
This clinical trial studies the following conditions: Clostridium Difficile.
What interventions are being tested in trial NCT02316470?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA84 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02316470?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02316470 being conducted?
This trial has 10 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
COMPLETED · Phase 2
-
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
COMPLETED · Phase 2
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
RECRUITING
-
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
ACTIVE NOT RECRUITING
-
Early FMT for C.Difficile
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.